The city of Miami, Florida, currently has 18 active clinical trials seeking participants for Dementia research studies.
Clinical Applications of Advanced Ophthalmic Imaging
NCT03135327
Recruiting
The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medica... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
09/12/2023
Locations: Bascom Palmer Eye Institute, Miami, Florida
Conditions: Multiple Sclerosis, Dry Eye Syndromes, Diabetic Retinopathy, Presbyopia, Myopia, Dementia
Register for Updates
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
NCT04838301
Recruiting
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
08/30/2023
Locations: Optimus U Corporation, Miami, Florida
Conditions: Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
Register for Updates
Trial of Parkinson's And Zoledronic Acid
NCT03924414
Recruiting
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the Nationa... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
07/24/2023
Locations: Parkinson's Foundation, Miami, Florida +1 locations
Conditions: Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
Register for Updates
Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test
NCT05107882
Recruiting
This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The CAS test is an adjunct to other diagnostic evaluations, and is indicated for use with the Optina Diagnostics' MHRC (K200254).
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
07/07/2023
Locations: Ezy Medical Research, Miami, Florida
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
Register for Updates
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
NCT03657745
Recruiting
Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLif... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
01/31/2023
Locations: Andrey Vyshedskiy, Miami, Florida
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognition Disorders in Old Age, Cognitive Decline, Cognitive Deterioration
Register for Updates
Longitudinal Cognitive Assessment by BoCA
NCT04114994
Recruiting
The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.
Gender:
All
Ages:
50 years and above
Trial Updated:
01/31/2023
Locations: Andrey Vyshedskiy, Miami, Florida
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia, Parkinson Disease, Multiple Sclerosis, TBI
Register for Updates